References
- Roberts P. J., Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer, 2002, 38 Suppl 5: S37–S38.
- van der Zwan S. M., DeMatteo R. P. Gastrointestinal stromal tumor: 5 years later. Cancer, 2005, 104: 1781–1788.
- Hirota S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279: 577–580.
- Heinrich M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299: 708–710.
- Demetri G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347: 472–480.
- Connolly E. M., Gaffney E., Reynolds J. V. Gastrointestinal stromal tumours. Br J Surg, 2003, 90: 1178–1186.
- Gervaz P., Huber o., Morel P. Surgical management of gastrointestinal stromal tumours. Br J Surg, 2009, 96: 567–578.
- Lo S. S. et al. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. Dis Colon Rectum, 2005, 48: 1316–1319.
- wasserberg N. et al. Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors ? Int J Colorectal Dis, 2007, 22: 981–982.
- Buess G. et al. [A system for a transanal endoscopic rectum operation]. Chirurg, 1984, 55: 677–680.
- Winde G. et al. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum, 1996, 39: 969–976.
- Eisenberg B. L. et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol, 2009, 99: 4247.
- Rutkowski P. et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol, 2013, 20: 2937–2943.
- Sicklick j. K., Lopez N. E. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors. J Gastrointest Surg, 2013, 17: 1997–2006.
- Tielen R. et al. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol, 2013, 39: 150–155.
- Tielen R. et al. Surgical management of rectal gastrointestinal stromal tumors. J Surg Oncol, 2013, 107: 320–323.
- Fujimoto Y. et al. Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum. Int J Colorectal Dis, 2013.
- Joensuu H. et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). ASCO Meeting Abstracts, 2011, 29: LBA1.